Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

AbbVie announces new results from Phase 3 GIFT-I study in GT1b HCV infected Japanese patients

Investing in new hepatitis C therapies may have significant economic impact

Investing in new hepatitis C therapies may have significant economic impact

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Investigational three-drug combination clears hepatitis C in 93% of patients with liver cirrhosis

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Sofosbuvir in combination with ribavirin/peginterferon achieves highest SVR rates in GT-3 HCV patients

Combination treatment effective for HCV genotype-1 mono-infected patients

Combination treatment effective for HCV genotype-1 mono-infected patients

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data supports use DAAs in patients with HCV recurrence following liver transplantation

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

Study: Combination therapy shows high SVR rates in HCV patients with decompensated liver disease

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

HCV-TARGET study: All-oral, direct-acting antiviral therapy for HCV effective in decompensated cirrhosis patients

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

Japanese MHLW grants priority review for AbbVie's investigational hepatitis C treatment

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

New HCV therapies cost-effective in specific groups of HCV-infected patients

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

Cancer could be broken down by its evolving defense mechanism

Cancer could be broken down by its evolving defense mechanism

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection